TAK-954
Sponsors
Takeda, Millennium Pharmaceuticals, Inc.
Conditions
Critical IllnessDiabetic GastroparesisEnteral Feeding IntoleranceEnteral NutritionHealthy ParticipantsHealthy VolunteersHepatic ImpairmentIdiopathic Gastroparesis
Phase 1
A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants
CompletedNCT03173170
Start: 2017-05-31End: 2017-07-24Updated: 2019-01-15
A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954
CompletedNCT03277274
Start: 2017-11-09End: 2018-09-10Updated: 2019-09-25
A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954
CompletedNCT03296787
Start: 2017-11-21End: 2019-08-09Updated: 2020-08-25
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants
CompletedNCT03870555
Start: 2019-03-08End: 2019-05-16Updated: 2020-06-24
Phase 2
Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
CompletedNCT03281577
Start: 2018-01-02End: 2019-07-12Updated: 2021-01-07
TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
TerminatedNCT03477903
Start: 2018-08-25End: 2018-08-29Updated: 2019-09-24
A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery
CompletedNCT03827655
Start: 2019-03-07End: 2022-05-27Updated: 2023-06-23